Asset profile
PEX168
Peptide
Evidence outlook · registrational
Type 2 Diabetes: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT01965509: The study randomized 120 participants to two PEX168 doses or placebo and used quadruple blinding, with HbA1c—a regulator-accepted clinical measure for type 2 diabetes—as the primary endpoint. However, no results or primary endpoint comparison are posted, so whether HbA1c improved cannot be assessed.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.